 On behalf of the Southwest Toncology Group 1500 study team, it's my pleasure today to unveil details of the PatMet clinical trial. The PatMet clinical trial is a study that's aimed at patients with metastatic papillary renal cell carcinoma. Papillary renal cell carcinoma is thought to comprise about 10 to 15% of renal cell carcinoma cases. Many reports today have suggested that the biology of papillary renal cell carcinoma is characterized by alternations along the met signaling pathway. Now the latter served as the rationale for a completed Southwest Toncology Group clinical trial evaluating ARCUL-197. This study, evaluating monotherapy with ARCUL-197 versus ARCUL-197 in combination with their lotinib, was reported as a negative study in ASCO 2015. However, ARCUL-197 is perhaps not the purest of the metinhibitors and then the current study will explore a number of other metinhibitors, which appear to have much greater specificity. What you see on the next slide is data for synitinib, which is considered the de facto standard currently for treating papillary renal cell carcinoma. This is based on both retrospective and prospective evidence. In the first series, here you see a response rate of 5% in a progression-free survival of 7.6 months. Other series, and this is a prospective series published by the M.D. Anderson Group, have proposed a 0% response rate in a progression-free survival of just 1.6 months. In the current study, we utilized synitinib's control arm, estimated progression-free survival of around 6 months, based on data from the SUPAP trial, which is listed in the third row here, where the response rate ranges between 11 and 13%, and the progression-free survival varies between 5.5 and 6.6 months based on the type of papillary renal cell carcinoma being characterized. There are also several studies exploring other metinhibitors that are currently at varying stages of clinical development. A study assessing Savalitinib, including 75 patients with both type 1 and type 2 disease, has yet to report out. But there are already discussions regarding phase 3 studies based on this data set that are evolving. There's a compound Insight 280 from Novartis, which is being assessed in the context of patients with hereditary or sporadic papillary renal cell carcinoma. And finally, Crozatinib is being assessed in the context of patients with papillary type 1 renal cell carcinoma. This data was actually just reported to ACR 2016, and in this study, amongst those patients that were noted to be met positive, there was an appreciable response rate noted, a confirmed PR in one of four patients and two of four patients in stable disease and an additional patient. In SWAG 1500, we will include patients with both type 1 and type 2 papillary renal cell carcinoma with measurable disease. Patients should have 0 to 1 prior lines of therapy. In this study, no prior therapy with Sinitinib is permitted. Patients should have a Zubrod performance status ranging between 0 and 1. Patients will be randomized in an equivalent fashion to either Sinitinib, Cabalatinib, Crozatinib, or Savalitinib with the primary endpoint of progression for resurvival. Note that in this trial, we do allow for both type 1 and type 2 disease, and if your local pathologist designates papillary type kidney cancer not otherwise specified, those patients would also be eligible for the current analysis. With respect to statistical considerations, we assume a progression-free survival associated with Sinitinib of six months based on the data that I presented to you previously. We assume that the successful progression-free survival at our appreciable PFS would be 10.5 months with the comparator arms. The study has one side at alpha of 0.1 and a beta error of 0.85. We anticipate a total of 164 patients enrolled. Assuming about 10% ineligibility, we assume that we'll need about 180 patients total accrued. Accrual to this study is more limited for patients with type 2 disease. In terms of our timeline for clinical development, we've gone through various phases already, invoking support from the Eastern Cooperative Oncology Group, the Alliance Cooperative Group, and most recently we've engaged the NCIC-CTG, allowing for participation from our Canadian colleagues. We've also received funding for extensive correlative studies looking at the role of med-alteration as a potential predictor of activity with these med-directed therapies. At present, this represents the one randomized effort in patients with papillary renal cell carcinoma that acknowledges the biology of the disease. This is an incredibly important trial, but given the rarity of papillary renal cell carcinoma, I feel that it will be vital for us to really focus our efforts together on this study and enroll quickly. We have an aggressive goal of enrolling six to eight patients per month, and if we make this study a priority in the renal cell carcinoma investigative community, I think that we can achieve that goal. Thank you so much for your interest.